Alzheimer’s Researchers Discover Bryostatin Can Slow, Reverse Disease Progression

Alzheimer’s Researchers Discover Bryostatin Can Slow, Reverse Disease Progression
Alzheimer's researchResearchers from the Blanchette Rockefeller Neuroscience Institute (BRNI) have gathered evidence of the possible role of protein kinase C epsilon (PKCe) in the treatment of Alzheimer's disease (AD). The news was recently announced by Neurotrope, a pharmaceutical company collaborating with BRNI in the development of bryostatin, a potent modulator of PKCe, for the treatment of patients suffering with AD. One of the big challenges in treating AD is the fact that patients typically start presenting with symptoms years after the disease is already present. The majority of treatments for AD have focused on stimulating the neurotransmitter activity of healthy neurons in the brain and in the ablation of the beta-amyloid plaque and tau protein that form as a result of the disease. However, so far, developing drugs specifically targeted at removing beta-amyloid plaque or tau protein has not been successful, and the existing drugs that stimulate neurotransmitter activity have not had an effect in the progression of the disease or in memory or cognitive performance improvement. In the recent study, entitled "PKCe Deficits in Alzheimer's Disease Brains and Skin Fibroblasts" and published in the Journal of
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *